Disseminated Tuberculosis With Ocular Involvement After 12 Years of Anti–TNF‐ α Therapy
Authors:
- Muhammad Ali MuslimaniMMMuhammad Ali Muslimani
- Silvia RossiSRSilvia Rossi
- Francesco SivieroFSFrancesco Siviero
- Armanda LekaALArmanda Leka
- Marco VecchiaMVMarco Vecchia
- Alessandra RicciardiARAlessandra Ricciardi
- Pietro ValsecchiPVPietro Valsecchi
- Raffaele BrunoRaffaele Bruno
- Angela Maria Di MatteoAMAngela Maria Di Matteo
Open Access
- 1 January 2026
- journal article
- Published by Wiley in Case Reports in Ophthalmological Medicine
- Vol. 2026 (1)
Abstract
Background: Ocular tuberculosis (TB) is an uncommon yet potentially vision‐threatening manifestation of Mycobacterium tuberculosis , particularly difficult to diagnose in immunocompromised individuals. The increasing use of anti–tumor necrosis factor‐ α (anti–TNF‐ α ) agents has markedly heightened the risk of TB reactivation, often with disseminated or extrapulmonary involvement despite negative baseline screening. Case Presentation: We describe a 52‐year‐old woman with rheumatoid arthritis receiving long‐term adalimumab and methotrexate who developed disseminated TB with pulmonary, splenic, and ocular involvement after 12 years of anti–TNF‐ α therapy. Baseline screening had shown a negative tuberculin skin test and an indeterminate interferon‐ γ release assay. She presented with constitutional and respiratory symptoms, whereas chest computed tomography demonstrated diffuse micronodular infiltrates consistent with miliary TB. Microbiological confirmation was obtained via bronchoalveolar lavage. Ophthalmologic evaluation revealed bilateral choroidal granulomas with subretinal edema, leading to a diagnosis of ocular TB. Standard antitubercular therapy (ATT) was initiated but required modification due to drug‐induced liver injury. Adjunctive systemic corticosteroids were introduced after antimicrobial therapy and gradually tapered. The patient achieved progressive clinical, radiological, and ophthalmologic improvement, with gradual regression of choroidal lesions. Discussion: This case underscores the persistent long‐term risk of TB reactivation during prolonged anti–TNF‐ α therapy and highlights the limitations of current screening strategies in immunosuppressed patients. Ocular TB requires integration of systemic, clinical, and imaging findings; in this patient, microbiologically confirmed disseminated TB together with characteristic bilateral choroidal granulomas supported a definitive diagnosis. Management relies on prompt ATT, discontinuation of immunosuppression, and judicious use of adjunctive corticosteroids. Long‐term follow‐up is essential given the risk of persistent lesions and late recurrence. Reintroduction of biologic therapy may be feasible in selected cases but requires careful risk stratification. Conclusion: TB should remain a diagnostic consideration in patients receiving biologic therapy who develop compatible systemic or ocular manifestations, even after long‐term treatment and negative baseline screening. Close multidisciplinary collaboration is essential for the diagnosis and management of ocular TB in this population.Keywords
This publication has 47 references indexed in Scilit:
- Uveitis in AdultsJAMA, 2025
- Validation of the Online Collaborative Ocular Tuberculosis Study Calculator for Tubercular UveitisJAMA Ophthalmology, 2024
- Disseminated, fatal reactivation of bovine tuberculosis in a patient treated with adalimumab: a case report and review of the literatureInfection, 2024
- (Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic reviewClinical Microbiology and Infection, 2024
- Clinical Features and Outcomes of Patients With Tubercular Uveitis Treated With Antitubercular Therapy in the Collaborative Ocular Tuberculosis Study (COTS)–1JAMA Ophthalmology, 2017
- Re-initiation of biologics after the development of tuberculosis under anti-TNF therapyRheumatology International, 2016
- Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United KingdomClinical Rheumatology, 2015
- Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practiceAutoimmunity Reviews, 2015
- Mycobacterial Ocular InflammationJAMA Ophthalmology, 2013
- Risk of developing tuberculosis under anti-TNF treatment despite latent infection screeningJournal of Crohn's and Colitis, 2013